Shelter Pharma to showcase products at Jaipur Ayurveda exhibition in September
- Shelter Pharma will exhibit at the Vishwa Ayurveda Parishad Exhibition in Jaipur
- The event takes place on September 17 and 18, 2026
- Company aims to strengthen ties with Ayurveda physicians and scholars
- Participation aligns with long-term brand visibility strategy

*this image is generated using AI for illustrative purposes only.
Shelter Pharma will participate in the Vishwa Ayurveda Parishad Exhibition in Jaipur on September 17 and 18, 2026. The company secured a stall to showcase its pharmaceutical portfolio.
The event is organized by the Vishwa Ayurveda Parishad in association with the National Institute of Ayurved (NIA), Jaipur. It forms part of a two-day National Ayurveda Workshop themed "Role of Ayurveda in Lifestyle Disorders".
Strategic Objectives
Management stated that participation aligns with long-term growth strategies. The company aims to achieve three primary outcomes through this engagement:
- Enhance global visibility and brand recognition
- Strengthen relationships with customers and business associations with Ayurveda professionals
- Introduce products and services to the professional community comprising physicians, scholars, and researchers
Regulatory Disclosure
The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mustaqim Nisar Ahmed Sabugar, Managing Director of Shelter Pharma Limited, signed the disclosure dated September 18, 2026.
Historical Stock Returns for Shelter Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +15.94% | +32.76% | +10.94% | -19.59% | -15.40% |
How might Shelter Pharma's participation in the Vishwa Ayurveda Parishad Exhibition influence its Q4 2026 revenue projections from the Ayurveda segment?
What specific new product launches or partnerships is Shelter Pharma expected to announce following its engagement with Ayurveda professionals at the Jaipur event?
Could this strategic pivot towards Ayurveda lead to increased regulatory scrutiny or require new compliance frameworks under SEBI guidelines for alternative medicine disclosures?


































